首页 > 最新文献

Lancet Microbe最新文献

英文 中文
Thank you to The Lancet Microbe statistical and peer reviewers in 2025 感谢《柳叶刀微生物》杂志2025年的统计和同行评审。
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2026-01-13 DOI: 10.1016/j.lanmic.2026.101350
The Lancet Microbe (Editors)
{"title":"Thank you to The Lancet Microbe statistical and peer reviewers in 2025","authors":"The Lancet Microbe (Editors)","doi":"10.1016/j.lanmic.2026.101350","DOIUrl":"10.1016/j.lanmic.2026.101350","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101350"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
USA300 North American epidemic meticillin-resistant Staphylococcus aureus in South America: new pathogenicity island USA300南美流行的耐甲氧西林金黄色葡萄球菌:新的致病性岛。
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2025-11-02 DOI: 10.1016/j.lanmic.2025.101276
Gregory Melocco , Karine Dantas , Herrison Fontana , Caroline L Martini , Elder Sano , Felipe Vasquez-Ponce , Johana Becerra , Bruna Fuga , Fernanda Esposito , Mateus R Ribas , Alessandro C O Silveira , Nilton Lincopan
{"title":"USA300 North American epidemic meticillin-resistant Staphylococcus aureus in South America: new pathogenicity island","authors":"Gregory Melocco , Karine Dantas , Herrison Fontana , Caroline L Martini , Elder Sano , Felipe Vasquez-Ponce , Johana Becerra , Bruna Fuga , Fernanda Esposito , Mateus R Ribas , Alessandro C O Silveira , Nilton Lincopan","doi":"10.1016/j.lanmic.2025.101276","DOIUrl":"10.1016/j.lanmic.2025.101276","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101276"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145453496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial resistance in bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae (2010–24): a systematic review and meta-analysis 由肺炎链球菌、脑膜炎奈瑟菌或流感嗜血杆菌引起的细菌性脑膜炎的抗微生物药物耐药性(2010-24):一项系统综述和荟萃分析
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2026-01-27 DOI: 10.1016/j.lanmic.2025.101238
Gilbert Lazarus MD , Benjamin Caddey MSc , Anna Dean DVM MIPH PhD , Florentina Febrina BSc MD , Vincent Kharisma Wangsaputra MD MRes , Shafira Permata Radiani SKM , Yindi Xiong MSc , Prof John M Conly MD FRCPC , Prof Herman W Barkema DVM PhD FCAHS , Lorenzo Pezzoli DVM MSc PhD , Esther van Kleef PhD , Olga Tosas Auguet DVM PhD , Prof Paul Turner MBBS PhD , Kavita U Kothari MSc , Silvia Bertagnolio MD PhD , Diego B Nobrega DVM MSc PhD , Raph L Hamers MD PhD
<div><h3>Background</h3><div>There are fragmented data on the patterns of antimicrobial resistance in the main bacterial pathogens causing meningitis, especially in low-income and middle-income countries (LMICs) where the disease burden is highest. This review aimed to estimate meningitis-specific prevalence of antimicrobial resistance and time trends, globally and for each of the WHO regions, for the main antimicrobials used to treat or prevent meningitis.</div></div><div><h3>Methods</h3><div>In this systematic review and meta-analysis, we systematically searched Embase, Global Health Database, and MEDLINE for original, peer-reviewed articles in any language, published between Jan 1, 2010, and May 16, 2024, describing people diagnosed with a microbiologically confirmed meningitis caused by <em>Streptococcus pneumoniae</em>, <em>Neisseria meningitidis</em>, or <em>Haemophilus influenzae</em>, with antimicrobial susceptibility testing results. We excluded reports that did not describe specimen type, sampling period, geographical setting, denominators, or proportions for single-agent and class resistance. We used multilevel random-effect meta-analysis on summary data to estimate the prevalence and time trends of antimicrobial resistance for relevant pathogen–antimicrobial combinations in each WHO region and globally. To assess article quality, we adopted the Microbiology Investigation Criteria for Reporting Objectively (MICRO) checklist. This review was registered with PROSPERO (CRD42019155379).</div></div><div><h3>Findings</h3><div>The search yielded 1503 studies. After the removal of 606 duplicates, 665 from title and abstract screening, and 140 from full-text screening, 92 reports were eligible for inclusion. A further four were removed due to duplicate datasets. We included 88 reports and extracted data on 16 441 clinical isolates from 37 countries across all WHO regions, mostly LMICs. For <em>S pneumoniae</em> (81 reports, 13 295 isolates), prevalence of antimicrobial resistance was highest in the Western Pacific and Eastern Mediterranean regions, ranging across WHO regions from 14·7% (95% CI 4·5–29·5) to 58·0% (34·9–79·5) for benzylpenicillin (27·4% [19·0–36·6] globally), and from 3·8% (0·0–13·7) to 20·6% (2·2–50·8) for third-generation cephalosporins (3GCs; 8·8% [4·3–14·6] globally). Benzylpenicillin resistance in <em>S pneumoniae</em> meningitis increased over time in LMICs, whereas benzylpenicillin and 3GC resistance decreased over time in high-income countries. For <em>N meningitidis</em> (11 reports, 3001 isolates), prevalence of antimicrobial resistance was highest in the African region, ranging across WHO regions from 9·4% (7·2–11·8) to 44·9% (0·0–100·0) for benzylpenicillin (24·7% [5·3–52·3] globally, increasing over time); from 0·0% (0·0–0·1) to 17·0% (0·0–100·0) for 3GCs (4·6% [0·0–19·4] globally); and from 0·0% (0·0–0·2) to 17·1% (0·0–100·0) for ciprofloxacin (3·7% [0·0-25·9] globally). Among <em>H influenzae</em> isolates (five re
背景:关于引起脑膜炎的主要细菌病原体的抗微生物药物耐药性模式的数据并不完整,特别是在疾病负担最高的低收入和中等收入国家。本综述旨在估计全球和世卫组织各区域用于治疗或预防脑膜炎的主要抗菌素的脑膜炎特异性抗菌素耐药性流行率和时间趋势。方法:在这项系统评价和荟萃分析中,我们系统地检索了Embase、全球健康数据库和MEDLINE,检索了2010年1月1日至2024年5月16日期间发表的任何语言的同行评审的原创文章,这些文章描述了被诊断为微生物学证实的由肺炎链球菌、脑膜炎奈瑟菌或流感嗜血杆菌引起的脑膜炎的患者,并进行了抗菌药物敏感性测试。我们排除了没有描述标本类型、采样周期、地理环境、分母或单药和类药抗性比例的报告。我们对汇总数据进行了多水平随机效应荟萃分析,以估计世界卫生组织各区域和全球相关病原体-抗菌药物组合的耐药性患病率和时间趋势。为了评估文章质量,我们采用了客观报告微生物调查标准(MICRO)检查表。本综述已在普洛斯彼罗注册(CRD42019155379)。研究结果:共检索了1503项研究。在删除606个重复、665个标题和摘要筛选、140个全文筛选后,92个报告符合纳入条件。由于重复的数据集,另外四个被删除。我们纳入了88份报告,并提取了来自世卫组织所有区域(主要是中低收入国家)37个国家的16441株临床分离株的数据。对于肺炎链球菌(81份报告,13 295株),西太平洋和东地中海区域的抗菌素耐药率最高,在世卫组织各区域中,青霉素耐药率为14.7%(95%可信区间为4.5 - 29.5)至58.0%(34.9 - 79.5)(全球范围为27.4%[19.0 - 36.6]),第三代头孢菌素耐药率为3.8%(0 - 13.7)至20.6%(2.2 - 50.8)(全球范围为8.8%[4.3 - 14.6])。在中低收入国家,肺炎链球菌脑膜炎对青霉素的耐药性随着时间的推移而增加,而在高收入国家,对青霉素和3GC的耐药性随着时间的推移而减少。对于脑膜炎奈恩菌(11份报告,3001株分离物),非洲区域的抗菌素耐药性流行率最高,在世卫组织各区域范围内,对青霉素的耐药性从9.4%(7.2 - 11.8)到44.9%(0.0 - 100.0)不等(全球24.7%[5.3 - 52.3],随着时间的推移而增加);从0·0%(0 * 0 - 0 * 1)17·0%(0·0 - 100·0)3 gc(4·6%(0·0-19·4)在全球范围内);环丙沙星从0.0%(0.0 - 0.2)到17.1%(0.0 - 100.0)(全球为3.7%[0.0 - 25.9])。全球流感嗜血杆菌分离株(5份报告,145株)中,51·2%(0·0-100·0)对氨苄西林耐药,8·4%(0·1- 28.4)对3GC耐药;世卫组织各区域的数据不足。纳入的报告中没有一个描述了所有13个MICRO强制性项目,中位数为4个(范围从1到6)项缺失。解释:细菌性脑膜炎的治疗受到耐药病原体增加的挑战,特别是影响到获得有效治疗可能有限的中低收入国家的患者。我们的研究结果呼吁加强国家抗菌素耐药性监测系统,以便更好地制定治疗指南和公共卫生干预措施。资助:弗莱明基金、美国疾病控制和预防中心以及世卫组织。
{"title":"Antimicrobial resistance in bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae (2010–24): a systematic review and meta-analysis","authors":"Gilbert Lazarus MD ,&nbsp;Benjamin Caddey MSc ,&nbsp;Anna Dean DVM MIPH PhD ,&nbsp;Florentina Febrina BSc MD ,&nbsp;Vincent Kharisma Wangsaputra MD MRes ,&nbsp;Shafira Permata Radiani SKM ,&nbsp;Yindi Xiong MSc ,&nbsp;Prof John M Conly MD FRCPC ,&nbsp;Prof Herman W Barkema DVM PhD FCAHS ,&nbsp;Lorenzo Pezzoli DVM MSc PhD ,&nbsp;Esther van Kleef PhD ,&nbsp;Olga Tosas Auguet DVM PhD ,&nbsp;Prof Paul Turner MBBS PhD ,&nbsp;Kavita U Kothari MSc ,&nbsp;Silvia Bertagnolio MD PhD ,&nbsp;Diego B Nobrega DVM MSc PhD ,&nbsp;Raph L Hamers MD PhD","doi":"10.1016/j.lanmic.2025.101238","DOIUrl":"10.1016/j.lanmic.2025.101238","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;There are fragmented data on the patterns of antimicrobial resistance in the main bacterial pathogens causing meningitis, especially in low-income and middle-income countries (LMICs) where the disease burden is highest. This review aimed to estimate meningitis-specific prevalence of antimicrobial resistance and time trends, globally and for each of the WHO regions, for the main antimicrobials used to treat or prevent meningitis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this systematic review and meta-analysis, we systematically searched Embase, Global Health Database, and MEDLINE for original, peer-reviewed articles in any language, published between Jan 1, 2010, and May 16, 2024, describing people diagnosed with a microbiologically confirmed meningitis caused by &lt;em&gt;Streptococcus pneumoniae&lt;/em&gt;, &lt;em&gt;Neisseria meningitidis&lt;/em&gt;, or &lt;em&gt;Haemophilus influenzae&lt;/em&gt;, with antimicrobial susceptibility testing results. We excluded reports that did not describe specimen type, sampling period, geographical setting, denominators, or proportions for single-agent and class resistance. We used multilevel random-effect meta-analysis on summary data to estimate the prevalence and time trends of antimicrobial resistance for relevant pathogen–antimicrobial combinations in each WHO region and globally. To assess article quality, we adopted the Microbiology Investigation Criteria for Reporting Objectively (MICRO) checklist. This review was registered with PROSPERO (CRD42019155379).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;The search yielded 1503 studies. After the removal of 606 duplicates, 665 from title and abstract screening, and 140 from full-text screening, 92 reports were eligible for inclusion. A further four were removed due to duplicate datasets. We included 88 reports and extracted data on 16 441 clinical isolates from 37 countries across all WHO regions, mostly LMICs. For &lt;em&gt;S pneumoniae&lt;/em&gt; (81 reports, 13 295 isolates), prevalence of antimicrobial resistance was highest in the Western Pacific and Eastern Mediterranean regions, ranging across WHO regions from 14·7% (95% CI 4·5–29·5) to 58·0% (34·9–79·5) for benzylpenicillin (27·4% [19·0–36·6] globally), and from 3·8% (0·0–13·7) to 20·6% (2·2–50·8) for third-generation cephalosporins (3GCs; 8·8% [4·3–14·6] globally). Benzylpenicillin resistance in &lt;em&gt;S pneumoniae&lt;/em&gt; meningitis increased over time in LMICs, whereas benzylpenicillin and 3GC resistance decreased over time in high-income countries. For &lt;em&gt;N meningitidis&lt;/em&gt; (11 reports, 3001 isolates), prevalence of antimicrobial resistance was highest in the African region, ranging across WHO regions from 9·4% (7·2–11·8) to 44·9% (0·0–100·0) for benzylpenicillin (24·7% [5·3–52·3] globally, increasing over time); from 0·0% (0·0–0·1) to 17·0% (0·0–100·0) for 3GCs (4·6% [0·0–19·4] globally); and from 0·0% (0·0–0·2) to 17·1% (0·0–100·0) for ciprofloxacin (3·7% [0·0-25·9] globally). Among &lt;em&gt;H influenzae&lt;/em&gt; isolates (five re","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101238"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global biological sample collections from tuberculosis studies: a scoping review 结核病研究的全球生物样本收集:范围审查。
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2025-12-22 DOI: 10.1016/j.lanmic.2025.101287
Cara Adolph PhD , Simon C Mendelsohn PhD , Laura E Via PhD , Leonardo Martinez PhD , Cecilia S Lindestam Arlehamn PhD , Prof David M Lewinsohn PhD , Jordi B Torrelles PhD , Prof Philip C Hill MD
Progress in tuberculosis vaccine development is hindered by the incomplete understanding of protective immunity and other disease mechanisms. An interconnected network of sample biorepositories from tuberculosis studies could help to address these gaps. To assess the feasibility of such a resource, we conducted a scoping review of tuberculosis observational studies and vaccine clinical trials. The included studies collected at least one biological sample from tuberculosis cases, contacts, or controls and had more than 100 participants. We contacted the corresponding authors of these studies to determine the sample availability and interest in interconnected biorepositories. For the period 2014–24, we identified 104 observational studies and 18 vaccine trials that collected biological samples from 35 075 tuberculosis cases, 39 450 contacts or controls, and 45 628 trial participants across 43 countries. The commonly collected samples were blood, human genomic DNA, RNA, and sputum. Interest among the contacted investigators was high. Interconnected sample biorepositories could facilitate large-scale investigations and accelerate progress towards tuberculosis vaccine development.
对保护性免疫和其他疾病机制的不完全了解阻碍了结核病疫苗开发的进展。一个相互联系的结核病研究样本生物储存库网络可以帮助解决这些差距。为了评估这种资源的可行性,我们对结核病观察性研究和疫苗临床试验进行了范围审查。纳入的研究至少从结核病例、接触者或对照中收集了一份生物样本,参与者超过100人。我们联系了这些研究的通讯作者,以确定样品的可用性和对互联生物库的兴趣。在2014-24年期间,我们确定了104项观察性研究和18项疫苗试验,从43个国家的35 075例结核病病例、39 450名接触者或对照者和45 628名试验参与者中收集了生物样本。通常采集的样本是血液、人类基因组DNA、RNA和痰。接触到的调查人员都很感兴趣。相互关联的样本生物储存库可以促进大规模调查并加速结核病疫苗开发的进展。
{"title":"Global biological sample collections from tuberculosis studies: a scoping review","authors":"Cara Adolph PhD ,&nbsp;Simon C Mendelsohn PhD ,&nbsp;Laura E Via PhD ,&nbsp;Leonardo Martinez PhD ,&nbsp;Cecilia S Lindestam Arlehamn PhD ,&nbsp;Prof David M Lewinsohn PhD ,&nbsp;Jordi B Torrelles PhD ,&nbsp;Prof Philip C Hill MD","doi":"10.1016/j.lanmic.2025.101287","DOIUrl":"10.1016/j.lanmic.2025.101287","url":null,"abstract":"<div><div>Progress in tuberculosis vaccine development is hindered by the incomplete understanding of protective immunity and other disease mechanisms. An interconnected network of sample biorepositories from tuberculosis studies could help to address these gaps. To assess the feasibility of such a resource, we conducted a scoping review of tuberculosis observational studies and vaccine clinical trials. The included studies collected at least one biological sample from tuberculosis cases, contacts, or controls and had more than 100 participants. We contacted the corresponding authors of these studies to determine the sample availability and interest in interconnected biorepositories. For the period 2014–24, we identified 104 observational studies and 18 vaccine trials that collected biological samples from 35 075 tuberculosis cases, 39 450 contacts or controls, and 45 628 trial participants across 43 countries. The commonly collected samples were blood, human genomic DNA, RNA, and sputum. Interest among the contacted investigators was high. Interconnected sample biorepositories could facilitate large-scale investigations and accelerate progress towards tuberculosis vaccine development.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101287"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145835050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemic potential of SFTSV: increasing evidence for non-vector-borne transmission SFTSV的流行潜力:越来越多的证据表明非媒介传播。
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2025-11-05 DOI: 10.1016/j.lanmic.2025.101271
Wen Zheng , Hong Zhou , Michael J Carr , Weifeng Shi
{"title":"Epidemic potential of SFTSV: increasing evidence for non-vector-borne transmission","authors":"Wen Zheng ,&nbsp;Hong Zhou ,&nbsp;Michael J Carr ,&nbsp;Weifeng Shi","doi":"10.1016/j.lanmic.2025.101271","DOIUrl":"10.1016/j.lanmic.2025.101271","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101271"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145477231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health security at genomic artificial intelligence–antimicrobial resistance frontiers in low-income countries 基因组人工智能的卫生安全——低收入国家抗菌素耐药性前沿。
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2025-11-07 DOI: 10.1016/j.lanmic.2025.101282
Dickson Aruhomukama , Dathan M Byonanebye , Francis Kakooza
{"title":"Health security at genomic artificial intelligence–antimicrobial resistance frontiers in low-income countries","authors":"Dickson Aruhomukama ,&nbsp;Dathan M Byonanebye ,&nbsp;Francis Kakooza","doi":"10.1016/j.lanmic.2025.101282","DOIUrl":"10.1016/j.lanmic.2025.101282","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101282"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145490811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Africa launches plan to eliminate cholera by 2030 非洲启动到2030年消除霍乱的计划。
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2025-11-07 DOI: 10.1016/j.lanmic.2025.101284
Munyaradzi Makoni
{"title":"Africa launches plan to eliminate cholera by 2030","authors":"Munyaradzi Makoni","doi":"10.1016/j.lanmic.2025.101284","DOIUrl":"10.1016/j.lanmic.2025.101284","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101284"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145490796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maldives achieves triple elimination of mother-to-child disease transmission 马尔代夫实现三次消除母婴疾病传播。
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2025-12-16 DOI: 10.1016/j.lanmic.2025.101322
Priya Venkatesan
{"title":"Maldives achieves triple elimination of mother-to-child disease transmission","authors":"Priya Venkatesan","doi":"10.1016/j.lanmic.2025.101322","DOIUrl":"10.1016/j.lanmic.2025.101322","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101322"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145795122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Convergence and global molecular epidemiology of Klebsiella pneumoniae plasmids harbouring the iuc3 virulence locus: a population genomic analysis 包含iuc3毒力位点的肺炎克雷伯菌质粒的趋同和全球分子流行病学:种群基因组分析。
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2026-01-06 DOI: 10.1016/j.lanmic.2025.101236
Marjorie J Gibbon PhD , Natacha Couto PhD , Keira Cozens MSc , Samia Habib PhD , Lauren Cowley PhD , Prof David M Aanensen PhD , Prof Jukka Corander PhD , Harry A Thorpe PhD , Marit A K Hetland MSc , Davide Sassera PhD , Cristina Merla PhD , Marta Corbella MSc , Carolina Ferrari MSc , Prof Katy M E Turner PhD , Kwanrawee Sirikanchana PhD , Punyawee Dulyayangkul PhD , Nisanart Charoenlap PhD , Prof Visanu Thamlikitkul MD , Prof Matthew B Avison PhD , Prof Edward J Feil PhD
<div><h3>Background</h3><div><em>Klebsiella pneumoniae</em> is an important pathogen of humans and animals. In the past five years, increasing reports of convergent strains that carry both virulence factors and antimicrobial resistance genes (ARGs) have raised serious public health concerns. The aim of this study is to describe the global diversity of plasmids carrying <em>iuc3</em> (a key virulence factor in <em>K pneumoniae</em> associated with pigs and clinical isolates) from diverse settings, and their role in the emergence of convergent strains through hybridisation with plasmids carrying ARGs.</div></div><div><h3>Methods</h3><div>This population genomic analysis study was designed to describe both the global and local diversity of <em>iuc3</em>-carrying plasmids from diverse sources, and the co-occurrence of <em>iuc3</em> with ARGs. We used all 4148 <em>Klebsiella</em> spp isolates from two large One-Health studies (SpARK, Italy, and OH-DART, Thailand), including 191 <em>Klebsiella</em> isolates from pigs, 635 from clinical isolates, 1040 from hospital and community carriage, and 2282 from other sources. Short-read sequencing of <em>Klebsiella</em> isolates was performed as part of the SpARK study. We sequenced <em>Klebsiella</em> isolates from the OH-DART (MicrobesNG, Birmingham, UK; HiSeq and NovaSeq, Illumina San Diego, CA, USA; GridION, Oxford Nanopore Technologies, Oxford, UK) and SpARK (MinION or GridION, Oxford Nanopore Technologies, Oxford, UK) studies. We also retrieved plasmid sequences carrying <em>iuc3</em> from the National Centre for Biotechnology Information (NCBI). To ascertain the degree of diversity, evolutionary dynamics, and structuring across ecological and geographical axes, we detected ARGs and virulence loci, analysed clustering patterns and generated approximate maximum-likelihood phylogenetic trees.</div></div><div><h3>Findings</h3><div>We identified 48 <em>K pneumoniae</em> isolates with <em>iuc3</em> in the SpARK data and 79 in the OH-DART data. Three (2·4%) of these 127 isolates were from clinical sources, 73 (57·5%) were from pig or pork meat. <em>iuc3</em> isolates corresponded to multiple (n=47) host sequence types (STs), with ST35, ST45, ST881, ST25, and ST967 harbouring <em>iuc3</em> in both datasets. We generated hybrid assemblies for 44 (SpARK) and 36 (OH-DART) isolates, plus a single <em>iuc3</em> isolate from Germany. 53 (65·4%) of these isolates were from pigs, three (3·7%) from clinical sources, and 25 (30·9%) from other sources. There were an additional 48 <em>iuc3</em> positive isolates from our collections for which only short read data was available. A single <em>iuc3</em>-positive <em>Klebsiella oxytoca</em> isolate from a pig farm was detected in the SpARK data, which was also sequenced. We identified 330 <em>iuc3</em>-positive isolates and 58 <em>iuc3</em>-carrying plasmid assemblies from NCBI, of which 83 (21·4%) were from clinical sources, 120 from pigs (30·9%), and 185 (47·7%) from other sou
背景:肺炎克雷伯菌是一种重要的人畜致病菌。在过去五年中,越来越多关于同时携带毒力因子和抗菌素耐药基因(ARGs)的趋同菌株的报道引起了严重的公共卫生问题。本研究的目的是描述来自不同环境的携带iuc3(与猪和临床分离的肺炎克雷伯菌相关的关键毒力因子)的质粒的全球多样性,以及它们通过与携带ARGs的质粒杂交在出现趋同菌株中的作用。方法:本群体基因组分析研究旨在描述来自不同来源的iuc3携带质粒的全球和局部多样性,以及iuc3与ARGs的共现性。我们使用了来自两项大型单一健康研究(意大利的SpARK和泰国的OH-DART)的全部4148株克雷伯氏菌分离株,包括191株来自猪的克雷伯氏菌分离株,635株来自临床分离株,1040株来自医院和社区运输,2282株来自其他来源。克雷伯菌分离株的短读测序作为SpARK研究的一部分进行。我们对OH-DART (MicrobesNG, Birmingham, UK; HiSeq和NovaSeq, Illumina San Diego, CA, USA; GridION, Oxford Nanopore Technologies, Oxford, UK)和SpARK (MinION或GridION, Oxford Nanopore Technologies, Oxford, UK)研究中的克雷伯菌分离株进行了测序。我们还从国家生物技术信息中心(NCBI)检索了携带iuc3的质粒序列。为了确定生态和地理轴上的多样性程度、进化动态和结构,我们检测了ARGs和毒力位点,分析了聚类模式,并生成了近似的最大似然系统发育树。结果:我们在SpARK数据中鉴定出48株含有iuc3的K肺炎分离株,在OH-DART数据中鉴定出79株。127株分离株中3株(2.4%)来自临床,73株(57.5%)来自猪或猪肉。iuc3分离株与多个(n=47)宿主序列类型(STs)相对应,在两个数据集中,ST35、ST45、ST881、ST25和ST967都含有iuc3。我们建立了44株(SpARK)和36株(OH-DART)分离株以及1株来自德国的iuc3分离株的杂交组合,其中53株(65.4%)来自猪,3株(3.7%)来自临床来源,25株(30.9%)来自其他来源。我们的收集中还有48株iuc3阳性分离株,只有短读数据可用。在SpARK数据中检测到来自猪场的单个iuc3阳性克雷伯菌,并对其进行了测序。我们从NCBI中鉴定出330株iuc3阳性分离株和58株携带iuc3的质粒,其中83株(21.4%)来自临床来源,120株(30.9%)来自猪,185株(47.7%)来自其他来源或来源不明。除2株似肺炎克雷伯菌和1株贺氏肠杆菌外,其余均为肺炎克雷伯菌分离株。517个iuc3质粒的组合数据集大小在110 375 bp ~ 365 580 bp之间,大部分对应多种IncFIB(K)和IncFII复制子类型。我们在泰国的数据中发现了7个趋同性肺炎克氏菌质粒:6个来自新鲜市场,1个来自邻近医院。这些质粒是通过共循环iuc3质粒和编码扩展谱β-内酰胺酶(ESBLs)的质粒杂交产生的,尽管这7个质粒都不携带编码碳青霉烯酶的基因。我们还发现了携带iuc3和esbl编码基因的推定共循环亲本质粒。聚类和系统发育分析将iuc3质粒序列分为三组,完整质粒序列(n=139)和短读数据(n=517)一致。在完整的质粒序列数据中,含有1组质粒的菌株有66株,含有2组质粒的菌株有38株,含有3组质粒的菌株有35株。第3组质粒主要由在亚洲各地医院传播的分离株携带,偶尔在欧洲和其他地方也有病例,并携带多种ARGs和潜在的毒力因子。相比之下,第1组质粒通常由欧洲的猪分离株携带,第2组质粒是地理和生态来源的异质混合物。解释:质粒杂交经常在卫生保健环境之外发生,并可能导致耐药性和毒力性状的趋同。从区域种群规模的样本中生成完整的质粒序列有助于鉴定聚合质粒及其假定的亲本质粒。三组iuc3质粒在流行病学和地理上均存在差异;其中一组与亚洲的临床分离株相关,需要有针对性的质粒监测。资助:UKRI, JPIAMR,进化教育信托基金和斯伦贝谢基金会奖学金。
{"title":"Convergence and global molecular epidemiology of Klebsiella pneumoniae plasmids harbouring the iuc3 virulence locus: a population genomic analysis","authors":"Marjorie J Gibbon PhD ,&nbsp;Natacha Couto PhD ,&nbsp;Keira Cozens MSc ,&nbsp;Samia Habib PhD ,&nbsp;Lauren Cowley PhD ,&nbsp;Prof David M Aanensen PhD ,&nbsp;Prof Jukka Corander PhD ,&nbsp;Harry A Thorpe PhD ,&nbsp;Marit A K Hetland MSc ,&nbsp;Davide Sassera PhD ,&nbsp;Cristina Merla PhD ,&nbsp;Marta Corbella MSc ,&nbsp;Carolina Ferrari MSc ,&nbsp;Prof Katy M E Turner PhD ,&nbsp;Kwanrawee Sirikanchana PhD ,&nbsp;Punyawee Dulyayangkul PhD ,&nbsp;Nisanart Charoenlap PhD ,&nbsp;Prof Visanu Thamlikitkul MD ,&nbsp;Prof Matthew B Avison PhD ,&nbsp;Prof Edward J Feil PhD","doi":"10.1016/j.lanmic.2025.101236","DOIUrl":"10.1016/j.lanmic.2025.101236","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;&lt;em&gt;Klebsiella pneumoniae&lt;/em&gt; is an important pathogen of humans and animals. In the past five years, increasing reports of convergent strains that carry both virulence factors and antimicrobial resistance genes (ARGs) have raised serious public health concerns. The aim of this study is to describe the global diversity of plasmids carrying &lt;em&gt;iuc3&lt;/em&gt; (a key virulence factor in &lt;em&gt;K pneumoniae&lt;/em&gt; associated with pigs and clinical isolates) from diverse settings, and their role in the emergence of convergent strains through hybridisation with plasmids carrying ARGs.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This population genomic analysis study was designed to describe both the global and local diversity of &lt;em&gt;iuc3&lt;/em&gt;-carrying plasmids from diverse sources, and the co-occurrence of &lt;em&gt;iuc3&lt;/em&gt; with ARGs. We used all 4148 &lt;em&gt;Klebsiella&lt;/em&gt; spp isolates from two large One-Health studies (SpARK, Italy, and OH-DART, Thailand), including 191 &lt;em&gt;Klebsiella&lt;/em&gt; isolates from pigs, 635 from clinical isolates, 1040 from hospital and community carriage, and 2282 from other sources. Short-read sequencing of &lt;em&gt;Klebsiella&lt;/em&gt; isolates was performed as part of the SpARK study. We sequenced &lt;em&gt;Klebsiella&lt;/em&gt; isolates from the OH-DART (MicrobesNG, Birmingham, UK; HiSeq and NovaSeq, Illumina San Diego, CA, USA; GridION, Oxford Nanopore Technologies, Oxford, UK) and SpARK (MinION or GridION, Oxford Nanopore Technologies, Oxford, UK) studies. We also retrieved plasmid sequences carrying &lt;em&gt;iuc3&lt;/em&gt; from the National Centre for Biotechnology Information (NCBI). To ascertain the degree of diversity, evolutionary dynamics, and structuring across ecological and geographical axes, we detected ARGs and virulence loci, analysed clustering patterns and generated approximate maximum-likelihood phylogenetic trees.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;We identified 48 &lt;em&gt;K pneumoniae&lt;/em&gt; isolates with &lt;em&gt;iuc3&lt;/em&gt; in the SpARK data and 79 in the OH-DART data. Three (2·4%) of these 127 isolates were from clinical sources, 73 (57·5%) were from pig or pork meat. &lt;em&gt;iuc3&lt;/em&gt; isolates corresponded to multiple (n=47) host sequence types (STs), with ST35, ST45, ST881, ST25, and ST967 harbouring &lt;em&gt;iuc3&lt;/em&gt; in both datasets. We generated hybrid assemblies for 44 (SpARK) and 36 (OH-DART) isolates, plus a single &lt;em&gt;iuc3&lt;/em&gt; isolate from Germany. 53 (65·4%) of these isolates were from pigs, three (3·7%) from clinical sources, and 25 (30·9%) from other sources. There were an additional 48 &lt;em&gt;iuc3&lt;/em&gt; positive isolates from our collections for which only short read data was available. A single &lt;em&gt;iuc3&lt;/em&gt;-positive &lt;em&gt;Klebsiella oxytoca&lt;/em&gt; isolate from a pig farm was detected in the SpARK data, which was also sequenced. We identified 330 &lt;em&gt;iuc3&lt;/em&gt;-positive isolates and 58 &lt;em&gt;iuc3&lt;/em&gt;-carrying plasmid assemblies from NCBI, of which 83 (21·4%) were from clinical sources, 120 from pigs (30·9%), and 185 (47·7%) from other sou","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101236"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145946562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular epidemiology of clinical carbapenem-resistant Citrobacter spp in China (2016–24) 中国临床耐碳青霉烯柠檬酸杆菌的分子流行病学(2016-24)
IF 20.4 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2026-02-01 Epub Date: 2025-09-23 DOI: 10.1016/j.lanmic.2025.101250
Ying Fu , Yanfei Wang , Bingyan Yao , Hua Zhou , Jintao He
{"title":"Molecular epidemiology of clinical carbapenem-resistant Citrobacter spp in China (2016–24)","authors":"Ying Fu ,&nbsp;Yanfei Wang ,&nbsp;Bingyan Yao ,&nbsp;Hua Zhou ,&nbsp;Jintao He","doi":"10.1016/j.lanmic.2025.101250","DOIUrl":"10.1016/j.lanmic.2025.101250","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"7 2","pages":"Article 101250"},"PeriodicalIF":20.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145179436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Microbe
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1